Clinical trials: Risk Stratification
Aortic Valve Disease, Pulmonary Valve Disease
Artificial Intelligence in New Cardiac MR Markers for Congenital Heart Disease
The goal of this study is to investigate children with aortic and pulmonary valve disease treated or untreated longitudinally. Established CMR measures with additional newly developped, promising, highly refined and clinically…
- Conditions
- Aortic Valve Disease, Pulmonary Valve Disease, Child, Only, Magnetic Resonance Imaging
- Trial name
- AI-CMR (NCT05979870)
- Testing
- Valvuloplasty,
- Where
- Sweden
- Volunteers
- 45 people
- Sponsor
- Sahlgrenska University Hospital
Ewing Sarcoma, Risk Stratification
Risk Stratification Oriented Treatment of Pediatric Ewing Sarcoma: a Prospective Multicenter Cohort Study
The aim is to evaluate the outcome and safety of risk-stratification oriented treatment for pediatric Ewing sarcoma in multicenters .
- Trial name
- NCT06451302
- Testing
- cyclophosphamide, adriamycin, vincristine，Ifosfamide，etoposide
- Where
- China
- Volunteers
- 100 people
- Sponsor
- Yizhuo Zhang
Wolff-Parkinson-White Syndrome, Sudden Cardiac Death
Stress ECG Test for the Evaluation of the Risk of Sudden Cardiac Death in a Paediatric Cohort With WPW Pattern
Patients with preexcitation are at risk for sudden cardiac death. The pathogenesis is a rapid antegrade conduction of atrial fibrillation over the accessory pathway to the ventricle resulting in ventricular fibrillation.
- Conditions
- Wolff-Parkinson-White Syndrome, Sudden Cardiac Death, Risk Stratification
- Trial name
- NCT03207373
- Testing
- Stress test (ECG)
- Where
- Switzerland
- Volunteers
- 3 people
- Sponsor
- Christian Balmer
Acute Myeloid Leukemia, Risk Stratification
Risk Stratification-directed Therapy for AML With t(8;21) /AML1-ETO+
Acute myeloid leukemia with t(8;21) /AML1-ETO-positive (AE AML) is a heterogeneous disease entailing different prognoses. There were significant differences in the therapeutic effect between different subgroups of AE AML.
- Trial name
- NCT02936089
- Testing
- Consolidation with chemotherapy (CT) or autologous hematopoietic stem cell transplantation (auto-HSCT), Consolidation with auto-HSCT or HLA-matched HSCT, allogeneic HSCT
- Volunteers
- 207 people
- Sponsor
- Nanfang Hospital, Southern Medical University
Triage, Risk Stratification With Biomarker
Risk Stratification in Acute Care: The Meaning of suPAR Measurement in Triage
Will clinical outcome for patients be improved if triage in Acute wards and Emergency rooms is supplemented with a prognostic biomarker?
- Trial name
- suPAR (NCT02643459)
- Testing
- suPAR measurement
- Where
- Denmark
- Volunteers
- 20,000 people
- Sponsor
- Herlev Hospital